Scancell Hldgs Plc Total Assets
Scancell Hldgs Plc total assets. Based on the latest financial reports, Scancell Hldgs Plc (SCLP) holds total assets worth GBX15.38 Million GBX (≈ $1.87K USD) as of October 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SCLP stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Scancell Hldgs Plc (2005–2025)
Total assets of Scancell Hldgs Plc from 2005 to 2025. This chart illustrates how Scancell Hldgs Plc's total assets have evolved over time, based on quarterly financial data. See Scancell Hldgs Plc stock quote for real-time trading data and today's change.
Scancell Hldgs Plc - Asset Composition Analysis
Scancell Hldgs Plc Total Assets Breakdown (April 2025)
Scancell Hldgs Plc total assets breakdown as of April 2025. Scancell Hldgs Plc's total assets of GBX15.38 Million consist of 89.3% current assets and 10.7% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 73.2% |
| Accounts Receivable | GBX3.73 Million | 16.2% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX1.62 Million | 7.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Scancell Hldgs Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Scancell Hldgs Plc (SCLP) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scancell Hldgs Plc's current assets represent 89.3% of total assets in 2025, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 73.2% of total assets in 2025, up from 60.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 16.2% of total assets.
Scancell Hldgs Plc Competitors by Total Assets
Key competitors of Scancell Hldgs Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Scancell Hldgs Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.56 | 0.43 | 3.99 |
| Quick Ratio | 0.56 | 0.43 | 4.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-10.48 Million | GBX-17.99 Million | GBX21.07 Million |
Scancell Hldgs Plc - Advanced Valuation Insights
This section examines the relationship between Scancell Hldgs Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.89 |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | GBX23.09 Million |
| Market Capitalization | $10.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scancell Hldgs Plc's assets below their book value (0.46x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Scancell Hldgs Plc's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Scancell Hldgs Plc (2005–2025)
The table below shows the annual total assets of Scancell Hldgs Plc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | GBX23.09 Million ≈ $2.81K |
-2.06% |
| 2024-04-30 | GBX23.58 Million ≈ $2.87K |
-22.11% |
| 2023-04-30 | GBX30.27 Million ≈ $3.68K |
-38.30% |
| 2022-04-30 | GBX49.06 Million ≈ $5.97K |
+456.34% |
| 2021-04-30 | GBX8.82 Million ≈ $1.07K |
-16.36% |
| 2020-04-30 | GBX10.54 Million ≈ $1.28K |
0.00% |
| 2019-04-30 | GBX10.54 Million ≈ $1.28K |
-27.98% |
| 2018-04-30 | GBX14.64 Million ≈ $1.78K |
+108.17% |
| 2017-04-30 | GBX7.03 Million ≈ $855.49 |
-33.47% |
| 2016-04-30 | GBX10.57 Million ≈ $1.29K |
+43.63% |
| 2015-04-30 | GBX7.36 Million ≈ $895.25 |
-23.47% |
| 2014-04-30 | GBX9.61 Million ≈ $1.17K |
+77.81% |
| 2013-04-30 | GBX5.41 Million ≈ $657.91 |
-25.48% |
| 2012-04-30 | GBX7.26 Million ≈ $882.81 |
+52.50% |
| 2011-04-30 | GBX4.76 Million ≈ $578.91 |
-26.80% |
| 2010-04-30 | GBX6.50 Million ≈ $790.86 |
+19.90% |
| 2009-04-30 | GBX5.42 Million ≈ $659.58 |
+377.39% |
| 2008-04-30 | GBX1.14 Million ≈ $138.16 |
-30.67% |
| 2007-04-30 | GBX1.64 Million ≈ $199.28 |
+181.90% |
| 2006-04-30 | GBX581.00K ≈ $70.69 |
-53.03% |
| 2005-08-31 | GBX1.24 Million ≈ $150.51 |
-- |
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more